Effects of nafarelin on bone density.

Jacobson JB

American journal of obstetrics and gynecology1 Feb 1990Cited by 6 (Europe PMC)

PMID2137978DOI10.1016/0002-9378(90)90439-ePepBankPUB-02137978

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialSafety outcome
In premenopausal women with endometriosis, bone mineral measurements remained constant during low-dose nafarelin treatment.
In plain wordsIn premenopausal women with endometriosis, bone mineral stayed constant during low-dose nafarelin treatment.
Peptide
Nafarelin
Outcome
No significant changeBone mineral during low-dose treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 micrograms/day · 6 monthsAs given in this study (human).
Source sentences
Summary
With low doses of nafarelin (200 micrograms/day), bone mineral measurements remained constant, whereas with high doses of the drug (400 micrograms/day) bone mineral levels decreased significantly.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the gonadotropin-releasing hormone analog nafarelin on bone metabolism during treatment of premenopausal women for endometriosis were evaluated in two studies, both of which involved 6 months of medication followed by 6 months without medication.
Report a problemFND-0213797801
02HumanNon-randomized trialSafety outcome
In premenopausal women with endometriosis, high-dose nafarelin significantly decreased bone mineral levels.
In plain wordsIn premenopausal women with endometriosis, high-dose nafarelin reduced bone mineral levels.
Peptide
Nafarelin
Outcome
DecreaseBone mineral during high-dose treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms/day · 6 monthsAs given in this study (human).
Source sentences
Summary
With low doses of nafarelin (200 micrograms/day), bone mineral measurements remained constant, whereas with high doses of the drug (400 micrograms/day) bone mineral levels decreased significantly.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the gonadotropin-releasing hormone analog nafarelin on bone metabolism during treatment of premenopausal women for endometriosis were evaluated in two studies, both of which involved 6 months of medication followed by 6 months without medication.
Report a problemFND-0213797802
03HumanNon-randomized trialSafety outcome
In premenopausal women with endometriosis, bone mineral measurements returned to normal within 6 months after nafarelin withdrawal.
In plain wordsIn premenopausal women with endometriosis, bone mineral returned to normal within 6 months after nafarelin stopped.
Peptide
Nafarelin
Outcome
Not applicableBone mineral recovery after withdrawal
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Within 6 months after treatment was stopped, however, bone mineral measurements returned to normal levels.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the gonadotropin-releasing hormone analog nafarelin on bone metabolism during treatment of premenopausal women for endometriosis were evaluated in two studies, both of which involved 6 months of medication followed by 6 months without medication.
Report a problemFND-0213797803
04HumanNon-randomized trialSafety outcome
In premenopausal women with endometriosis, low-dose nafarelin significantly increased bone resorption.
In plain wordsIn premenopausal women with endometriosis, low-dose nafarelin increased bone resorption.
Peptide
Nafarelin
Outcome
IncreaseBone resorption during low-dose treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 micrograms/day · 6 monthsAs given in this study (human).
Source sentences
Summary
Both dosages of nafarelin resulted in significant increases in bone resorption, but these determinations also returned to pretreatment values after drug therapy was stopped.
2 context sentences(design, population, supporting numbers)
Summary · context
With low doses of nafarelin (200 micrograms/day), bone mineral measurements remained constant, whereas with high doses of the drug (400 micrograms/day) bone mineral levels decreased significantly.
Summary · context
The effects of the gonadotropin-releasing hormone analog nafarelin on bone metabolism during treatment of premenopausal women for endometriosis were evaluated in two studies, both of which involved 6 months of medication followed by 6 months without medication.
Report a problemFND-0213797804
05HumanNon-randomized trialSafety outcome
In premenopausal women with endometriosis, high-dose nafarelin significantly increased bone resorption.
In plain wordsIn premenopausal women with endometriosis, high-dose nafarelin increased bone resorption.
Peptide
Nafarelin
Outcome
IncreaseBone resorption during high-dose treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms/day · 6 monthsAs given in this study (human).
Source sentences
Summary
Both dosages of nafarelin resulted in significant increases in bone resorption, but these determinations also returned to pretreatment values after drug therapy was stopped.
2 context sentences(design, population, supporting numbers)
Summary · context
With low doses of nafarelin (200 micrograms/day), bone mineral measurements remained constant, whereas with high doses of the drug (400 micrograms/day) bone mineral levels decreased significantly.
Summary · context
The effects of the gonadotropin-releasing hormone analog nafarelin on bone metabolism during treatment of premenopausal women for endometriosis were evaluated in two studies, both of which involved 6 months of medication followed by 6 months without medication.
Report a problemFND-0213797805
06HumanNon-randomized trialSafety outcome
In premenopausal women with endometriosis, bone resorption returned to pretreatment values after low-dose nafarelin withdrawal.
In plain wordsIn premenopausal women with endometriosis, bone resorption returned to baseline after low-dose nafarelin stopped.
Peptide
Nafarelin
Outcome
Not applicableBone resorption after low-dose withdrawal
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 micrograms/day · 6 monthsAs given in this study (human).
Source sentences
Summary
Both dosages of nafarelin resulted in significant increases in bone resorption, but these determinations also returned to pretreatment values after drug therapy was stopped.
2 context sentences(design, population, supporting numbers)
Summary · context
With low doses of nafarelin (200 micrograms/day), bone mineral measurements remained constant, whereas with high doses of the drug (400 micrograms/day) bone mineral levels decreased significantly.
Summary · context
The effects of the gonadotropin-releasing hormone analog nafarelin on bone metabolism during treatment of premenopausal women for endometriosis were evaluated in two studies, both of which involved 6 months of medication followed by 6 months without medication.
Report a problemFND-0213797806
07HumanNon-randomized trialSafety outcome
In premenopausal women with endometriosis, bone resorption returned to pretreatment values after high-dose nafarelin withdrawal.
In plain wordsIn premenopausal women with endometriosis, bone resorption returned to baseline after high-dose nafarelin stopped.
Peptide
Nafarelin
Outcome
Not applicableBone resorption after high-dose withdrawal
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
400 micrograms/day · 6 monthsAs given in this study (human).
Source sentences
Summary
Both dosages of nafarelin resulted in significant increases in bone resorption, but these determinations also returned to pretreatment values after drug therapy was stopped.
2 context sentences(design, population, supporting numbers)
Summary · context
With low doses of nafarelin (200 micrograms/day), bone mineral measurements remained constant, whereas with high doses of the drug (400 micrograms/day) bone mineral levels decreased significantly.
Summary · context
The effects of the gonadotropin-releasing hormone analog nafarelin on bone metabolism during treatment of premenopausal women for endometriosis were evaluated in two studies, both of which involved 6 months of medication followed by 6 months without medication.
Report a problemFND-0213797807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.